The R21/Matrix-M malaria vaccine has a good safety profile and high efficacy in children from Africa.

Published Date: 07 Feb 2024

The Oxford University and Serum Institute of India Pvt Ltd-developed R21/Matrix-M vaccine, which uses Novavax's Matrix-M adjuvant, has demonstrated high efficacy in Phase III trial results, thereby supporting regulatory approvals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Examines Office-Based Transperineal Prostate Biopsies Methodology.

2.

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

3.

Is a $2,000 Whole-Body MRI Worth It?

4.

Surgery may not be necessary to treat invasive breast cancer

5.

Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot